Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.

Collette, Fanny;Lawson, Georges;Hassid, Samantha;Delahaut, Gilles;D'Hondt, Lionel;et.al.
(2023) Head & Neck : journal for the sciences and specialities of the head and neck — Vol. 45, n° 5, p. 1071-1079 (2023)

Files

ColletteFHeadNeck2023.pdf
  • Open Access
  • Adobe PDF
  • 730.52 KB
Download

Details

Authors
Show more
Abstract
(en) BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a currently incurable benign neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice, respiratory, and general quality of life, and is sometimes life-threatening. Patients usually need repeated operations. The use of adjuvant bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, has been described in several case reports, with a good efficacy and safety profile. METHODS: We report the cases of five patients with aggressive RRP who were treated with adjuvant systemic bevacizumab in a single Belgian tertiary center. RESULTS: A complete response was achieved in four patients after a median of 4.5 months, and a partial response in one. In all cases, the number of surgeries was drastically reduced, and quality of life improved. Toxicity was easily managed. CONCLUSIONS: Systemic bevacizumab seems to be an effective and safe adjuvant treatment for aggressive RRP.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Collette, F., Lawson, G., Hassid, S., Delahaut, G., Bachy, V., Van Der Vorst, S., Faugeras, L., Gilliaux, Q., & D’Hondt, L. (2023). Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience. Head & Neck : journal for the sciences and specialities of the head and neck, 45(5), 1071-1079. https://doi.org/10.1002/hed.27300 (Original work published 2023)